This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Sep 2011

Debiopharm Signs Licence Agreement with Ascenta for Cancer Drug

The two companies have signed an exclusive licence agreement for the development and commercialization of a tumours treatment currently in Phase I development.

Swiss-based global biopharmaceutical group Debiopharm Group and privately-held clinical stage biopharmaceutical company Ascenta Therapeutics have signed an exclusive licence agreement for the development and commercialization of AT-406 for the treatment of tumours.


AT-406, the new drug candidate called Debio 1143 by Debiopharm, induces cancer cell death by targeting inhibitors of apoptosis proteins.


The drug is in Phase I development and is expected to be effective in the treatment of various cancers in combination with other anti-cancer therapies.


Debiopharm president and founder Rolland-Yves Mauvernay said it should be possible to combine AT-406 with other pro-apoptot

Related News